Clinical significance of circulating FcγRIIa in the prognosis of patients with metastatic non-small cell lung cancer
Xiaojie Wang, Yu Teng, Mei Jiang, Xiaoting Zhao, Xiaokui Yang, Wentao Yue · 2026
Read Clinical significance of circulating FcγRIIa in the prognosis of patients with metastatic non-small cell lung cancer by Xiaojie Wang, Yu Teng, Mei Jiang, Xiaoting Zhao, Xiaokui Yang, Wentao Yue (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13396060.txt.
Description
Xiaojie Wang and colleagues test circulating FcγRIIa as a prognosis marker in metastatic non-small cell lung cancer in a 2026 study. This receptor on platelets and immune cells activates inflammation and may promote tumor growth and spread, yet its blood levels across cancer types were little studied.
Serum from 333 patients with stage I to IV lung cancer and 100 healthy volunteers was analyzed, with levels markedly higher in patients, especially advanced cases. The team linked levels to clinical outcomes statistically. Oncologists gain a blood-based candidate for gauging prognosis in lung cancer.
Catalog record
| CREATOR | Xiaojie Wang, Yu Teng, Mei Jiang, Xiaoting Zhao, Xiaokui Yang, Wentao Yue |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |